NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 25 04:00PM ET
2.33
Dollar change
+0.03
Percentage change
1.11
%
Index- P/E- EPS (ttm)-10.34 Insider Own1.95% Shs Outstand1.39M Perf Week9.93%
Market Cap3.24M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.36M Perf Month-11.93%
Income-13.56M PEG- EPS next Q- Inst Own2.70% Short Float0.88% Perf Quarter-30.17%
Sales0.00M P/S- EPS this Y- Inst Trans11.18% Short Ratio1.42 Perf Half Y-28.20%
Book/sh4.32 P/B0.54 EPS next Y- ROA-52.28% Short Interest0.01M Perf Year-46.30%
Cash/sh12.69 P/C0.18 EPS next 5Y- ROE-84.53% 52W Range1.84 - 5.38 Perf YTD-33.00%
Dividend Est.- P/FCF- EPS past 5Y29.61% ROI-231.23% 52W High-56.78% Beta1.29
Dividend TTM- Quick Ratio17.47 Sales past 5Y0.00% Gross Margin- 52W Low26.36% ATR (14)0.19
Dividend Ex-Date- Current Ratio17.47 EPS Y/Y TTM76.16% Oper. Margin- RSI (14)49.15 Volatility5.21% 8.04%
Employees6 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price14.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-226.58% Payout- Rel Volume0.36 Prev Close2.30
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume8.44K Price2.33
SMA204.42% SMA50-9.31% SMA200-25.79% Trades Volume3,023 Change1.11%
Dec-20-24 09:15AM
Sep-11-24 09:00AM
Aug-16-24 09:52PM
Jul-18-24 09:00AM
Jun-26-24 09:00AM
11:54AM Loading…
May-20-24 11:54AM
May-07-24 09:00AM
Apr-24-24 09:15AM
Apr-09-24 09:15AM
Apr-03-24 08:00AM
Dec-19-23 09:00AM
Dec-06-23 09:00AM
Nov-02-23 09:00AM
Sep-26-23 09:00AM
Sep-07-23 09:00AM
09:00AM Loading…
Jul-19-23 09:00AM
Jul-13-23 09:00AM
Mar-07-23 09:00AM
Dec-16-22 09:00AM
Nov-18-22 09:00AM
Oct-19-22 09:00AM
Sep-28-22 11:50AM
Aug-12-22 09:00AM
Jul-26-22 09:15AM
Jul-21-22 09:15AM
Jul-20-22 09:15AM
May-17-22 09:15AM
Apr-19-22 09:15AM
Apr-05-22 09:15AM
Mar-29-22 09:15AM
09:15AM Loading…
Mar-22-22 09:15AM
Mar-15-22 09:15AM
Feb-23-22 09:15AM
Feb-07-22 09:38AM
Feb-01-22 09:15AM
Dec-06-21 11:58AM
Sep-28-21 09:00AM
Sep-10-21 09:00AM
Aug-05-21 10:00AM
Jul-26-21 09:15AM
Jul-21-21 09:00AM
Jul-14-21 09:00AM
Jul-07-21 09:00AM
Jun-24-21 09:00AM
Jun-14-21 09:00AM
Jun-09-21 09:00AM
05:38AM
May-19-21 09:00AM
May-10-21 09:00AM
Apr-26-21 09:00AM
Apr-01-21 09:00AM
Mar-05-21 09:00AM
Feb-25-21 09:12AM
Feb-12-21 09:00AM
Feb-09-21 09:00AM
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer's disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson's Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.